Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69


Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.


Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.

Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ.

J Oncol Pract. 2018 Jul;14(7):e421-e428. doi: 10.1200/JOP.18.00093. Epub 2018 Jun 25.


Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M.

J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.


Assessing changes in quality of life and independent living and working levels among AgrAbility farmers and ranchers with disabilities.

Fetsch RJ, Jackman DM, Collins CL.

Disabil Health J. 2018 Apr;11(2):230-236. doi: 10.1016/j.dhjo.2017.08.001. Epub 2017 Aug 8.


Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

Jackman DM, Zhang Y, Dalby C, Nguyen T, Nagle J, Lydon CA, Rabin MS, McNiff KK, Fraile B, Jacobson JO.

J Oncol Pract. 2017 Apr;13(4):e346-e352. doi: 10.1200/JOP.2017.021741. Epub 2017 Mar 4.


Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.

Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, Chen AB, Jackman DM, Kozono D, Swanson SJ, Wee JO, Aerts HJ, Mak RH.

Lung Cancer. 2016 Dec;102:1-8. doi: 10.1016/j.lungcan.2016.10.002. Epub 2016 Oct 14.


Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM.

JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304. No abstract available.


A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.


Alcohol consumption among rural African American and White adolescents: The role of religion, parents, and peers.

Dickens DD, Jackman DM, Stanley LR, Swaim RC, Chavez EL.

J Ethn Subst Abuse. 2018 Jul-Sep;17(3):273-290. doi: 10.1080/15332640.2016.1179155. Epub 2016 May 31.


MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.

J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.


Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE.

J Thorac Oncol. 2016 Apr;11(4):556-65. doi: 10.1016/j.jtho.2015.12.103. Epub 2015 Dec 25.


Quality of life and independent living and working levels of farmers and ranchers with disabilities.

Jackman DM, Fetsch RJ, Collins CL.

Disabil Health J. 2016 Apr;9(2):226-33. doi: 10.1016/j.dhjo.2015.09.002. Epub 2015 Nov 5.


Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.


Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR.

J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20.


Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR.

Cancer. 2015 Aug 1;121(15):2570-7. doi: 10.1002/cncr.29397. Epub 2015 Apr 15.


A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S.

Oncotarget. 2015 Feb 28;6(6):4527-36.


Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA.

Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.


Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE.

Eur J Radiol. 2015 May;84(5):998-1004. doi: 10.1016/j.ejrad.2015.01.021. Epub 2015 Feb 7.


Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M; National comprehension cancer network.

J Natl Compr Canc Netw. 2015 Jan;13(1):23-34; quiz 34.


Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.

Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM.

Lung Cancer. 2014 Aug;85(2):239-44. doi: 10.1016/j.lungcan.2014.06.001. Epub 2014 Jun 6.


Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):880-7. doi: 10.1016/j.ijrobp.2014.04.007. Epub 2014 May 24.


Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.

Nishino M, Jackman DM, DiPiro PJ, Hatabu H, Jänne PA, Johnson BE.

Clin Radiol. 2014 Aug;69(8):841-8. doi: 10.1016/j.crad.2014.03.020. Epub 2014 May 22.


Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.

Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.


Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV.

Oncologist. 2013;18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26.


Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.

Cancer. 2013 Nov 1;119(21):3761-8. doi: 10.1002/cncr.28290. Epub 2013 Aug 6.


RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

AJR Am J Roentgenol. 2013 Jul;201(1):W64-71. doi: 10.2214/AJR.12.9668.


Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

J Thorac Oncol. 2013 Aug;8(8):1059-68. doi: 10.1097/JTO.0b013e318294c909.


Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.

J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.


Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB.

Lung Cancer. 2013 Mar;79(3):193-7. doi: 10.1016/j.lungcan.2012.12.002. Epub 2012 Dec 27.


Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.

Lung Cancer. 2013 Mar;79(3):283-8. doi: 10.1016/j.lungcan.2012.11.007. Epub 2012 Dec 14.


The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-1774. doi: 10.1097/JTO.0b013e3182745bcb.


Pathologic characteristics of NUT midline carcinoma arising in the mediastinum.

Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM.

Am J Surg Pathol. 2012 Aug;36(8):1222-7. doi: 10.1097/PAS.0b013e318258f03b.


Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.

Cancer Imaging. 2012 Jun 29;12:225-35. doi: 10.1102/1470-7330.2012.0027.


The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.


Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W.

Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20.


Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV.

Oncologist. 2011;16(6):886-95. doi: 10.1634/theoncologist.2011-0040. Epub 2011 May 31.


Imaging of lung cancer in the era of molecular medicine.

Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.

Acad Radiol. 2011 Apr;18(4):424-36. doi: 10.1016/j.acra.2010.10.020. Epub 2011 Jan 28. Review.


CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.

Acad Radiol. 2011 Jan;18(1):54-62. doi: 10.1016/j.acra.2010.08.021. Epub 2010 Oct 30.


Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28.


New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.

Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.

AJR Am J Roentgenol. 2010 Sep;195(3):W221-8. doi: 10.2214/AJR.09.3928.


EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.

Am J Clin Pathol. 2010 Jun;133(6):922-34. doi: 10.1309/AJCPST1CTHZS3PSZ.


Current options for systemic therapy in mesothelioma.

Jackman DM.

Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):154-8. doi: 10.1053/j.semtcvs.2009.06.010. Review.


Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.

Clin Cancer Res. 2009 Aug 15;15(16):5267-73. doi: 10.1158/1078-0432.CCR-09-0888. Epub 2009 Aug 11.


Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.

Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455.


Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA.

Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.


Treatment of peritoneal mesothelioma in pediatric patients.

Cioffredi LA, Jänne PA, Jackman DM.

Pediatr Blood Cancer. 2009 Jan;52(1):127-9. doi: 10.1002/pbc.21718.


Shark skeletal muscle tropomyosin is a phosphoprotein.

Hayley M, Chevaldina T, Mudalige WA, Jackman DM, Dobbin AD, Heeley DH.

J Muscle Res Cell Motil. 2008;29(2-5):101-7. doi: 10.1007/s10974-008-9143-z. Epub 2008 Sep 2.


Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA.

Cancer. 2008 Aug 15;113(4):808-14. doi: 10.1002/cncr.23617.


Some binding properties of Omp T digested muscle tropomyosin.

Goonasekara CL, Gallivan LJ, Jackman DM, Heeley DH.

J Muscle Res Cell Motil. 2007;28(2-3):175-82. Epub 2007 Sep 6.


A vertebrate slow skeletal muscle actin isoform.

Mudalige WA, Jackman DM, Waddleton DM, Heeley DH.

FEBS J. 2007 Jul;274(13):3452-61. Epub 2007 Jun 6.

Supplemental Content

Loading ...
Support Center